SCHEMBL884143

SCHEMBL884143

Clc1ccc2c(c1)[CH]CN2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 3/20 0.37
CHEK1 O14757 1/20 0.36
LIMK1 P53667 1/20 0.36
TGM2 P21980 1/20 0.34
CES1 P23141 1/20 0.34
HTR2C P28335 4/20 0.34
HTR5A P47898 3/20 0.34
HTR2A P28223 3/20 0.34
HTR2B P41595 3/20 0.34
ADRA2A P08913 2/20 0.34
ADRA2B P18089 2/20 0.34
ADRA2C P18825 2/20 0.34
DRD4 P21917 2/20 0.34
HTR1D P28221 2/20 0.34
HTR7 P34969 2/20 0.34
HTR3A P46098 2/20 0.34
CMA1 P23946 2/20 0.33
ALDH1A1 P00352 2/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL886767 0.83 AHR (0.37) AHRCHEK1LIMK1CES1HTR2C
SCHEMBL1257327 0.79 AHR (0.35) AHRCHEK1LIMK1TGM2CES1
SCHEMBL4731226 0.74 HTR5A (0.34) AHRHTR2CHTR5AALDH1A1L3MBTL1
SCHEMBL3910092 0.74 BRD4 (0.37) AHRTGM2CES1CMA1NCF1
SCHEMBL6829817 0.69 KDM4E (0.53) HTR7ALDH1A1SMN1; SMN2
SCHEMBL6441945 0.66 AHR (0.50) AHRTGM2CES1CMA1TSHR
SCHEMBL9382768 0.65 DRD4 (0.40) AHRCHEK1LIMK1TGM2CES1
SCHEMBL24731749 0.65 CHEK1 (0.44) AHRCHEK1LIMK1TGM2CES1
SCHEMBL8089058 0.65 KDM4E (0.48) AHRCHEK1LIMK1TGM2CES1
SCHEMBL22050043 0.63 AVPR1A (0.45) HTR2CHTR2AHTR2BDRD4HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2615096-A1 QUINOXALINE COMPOUND Astellas Pharma Inc. (JP) 2013-07-17 EP claimed
EP-2018371-A1 PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2009-01-28 EP claimed
WO-2007136703-A1 PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2007-11-29 WO claimed
EP-2018371-A1 PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2009-01-28 EP disclosed
WO-2007136703-A1 PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2007-11-29 WO disclosed